Pharvaris to Present in Upcoming March Investor Conferences
March 02 2023 - 6:50AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced that
management will participate in two upcoming investor conferences in
March:
BioCapital Europe 2023Format: Live In-Person
PresentationDate/Time: Thursday, March 9, 2023, at 11:00 a.m. CET
(5:00 a.m. EST)Location: Amsterdam, Netherlands
Oppenheimer 33rd Annual Healthcare
ConferenceFormat: Webcasted Virtual PresentationDate/Time:
Monday, March 13, 2023, at 2:00 p.m. CET (8:00 a.m. EST)Location:
Virtual
A live audio webcast of the Oppenheimer 33rd Annual Healthcare
Conference presentation will be available on the Investors section
of the Pharvaris website at:
https://ir.pharvaris.com/news-events/events-presentations. A replay
will be available on Pharvaris’ website for 30 days following the
presentation.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE safe, effective, and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
ContactMaryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Sep 2023 to Sep 2024